From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.
Paulo Ricardo CriadoHélio Amante MiotThais Prota Hussein PincelliAlexandre Todorovic FabroPublished in: Dermatologic therapy (2020)
COVID-19 generates a complex systemic inflammatory response that can lead to death due to wide macrophage activation, endothelial damage, and coagulation in critically ill patients. SARS-CoV-2-induced lung injury due to inflammatory mediated thrombosis could be similar to the livedoid vasculopathy in the skin, supporting a translational comparison of these clinical settings. In this article, we discuss anticoagulation, suppression of inflammatory response, and hyperbaric oxygen therapy in the context of severe COVID-19 and livedoid vasculopathy.
Keyphrases
- sars cov
- inflammatory response
- coronavirus disease
- oxidative stress
- respiratory syndrome coronavirus
- atrial fibrillation
- lipopolysaccharide induced
- lps induced
- drug induced
- diabetic rats
- toll like receptor
- pulmonary embolism
- endothelial cells
- adipose tissue
- early onset
- stem cells
- soft tissue
- mesenchymal stem cells
- bone marrow